Physician profile
Devendra Amin
NPI 1760452973
$11,705.23
in general payments reported to CMS, 2019-2025
24 companies · $2,025 in 2025
The $2,025 reported for 2025 was more than what 94% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,645 · 2020: $1,414 · 2021: $1,886 · 2022: $1,348 · 2023: $1,401 · 2024: $1,987 · 2025: $2,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,352 · Education: $60.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,351.53 |
| Education | $60.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,434.96 | 2019-2025 | Wainua, Brilinta, Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,100.70 | 2019-2025 | Jardiance |
| Amgen INC. | $1,516.23 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $989.84 | 2019-2025 | |
| Esperion Therapeutics, INC. | $821.36 | 2020-2025 | Nexletol |
| Novartis Pharmaceuticals Corporation | $744.60 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $739.91 | 2019-2024 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $362.43 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $355.50 | 2019-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $339.21 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $247.04 | 2020-2025 | Wegovy, Ozempic, Rybelsus |
| Actelion Pharmaceuticals US, INC. | $166.18 | 2019-2023 | Opsumit, Uptravi |
| Sanofi-Aventis U.S. LLC | $150.53 | 2019 | |
| Boston Scientific Corporation | $145.73 | 2019-2023 | Bodyguardian |
| Kowa Pharmaceuticals America, INC. | $122.24 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $108.26 | 2019 | |
| Alnylam Pharmaceuticals INC. | $99.41 | 2025 | Onpattro |
| Scpharmaceuticals INC. | $65.58 | 2024 | |
| Bridgebio Pharma, INC. | $61.67 | 2025 | Attruby |
| Preventice Services, LLC | $40.27 | 2019 | |
| Kestra Medical Technology Services, INC. | $35.90 | 2025 | Assure Wcd |
| United Therapeutics Corporation | $21.20 | 2020 | |
| Lilly USA, LLC | $18.74 | 2025 | Mounjaro, Zepbound |
| Medtronic, INC. | $17.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devendra Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.